Literature DB >> 22296787

Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data.

K Y Yeung1, T A Gooley, A Zhang, A E Raftery, J P Radich, V G Oehler.   

Abstract

MOTIVATION: Selecting a small number of signature genes for accurate classification of samples is essential for the development of diagnostic tests. However, many genes are highly correlated in gene expression data, and hence, many possible sets of genes are potential classifiers. Because treatment outcomes are poor in advanced chronic myeloid leukemia (CML), we hypothesized that expression of classifiers of advanced phase CML when detected in early CML [chronic phase (CP) CML], correlates with subsequent poorer therapeutic outcome.
RESULTS: We developed a method that integrates gene expression data with expert knowledge and predicted functional relationships using iterative Bayesian model averaging. Applying our integrated method to CML, we identified small sets of signature genes that are highly predictive of disease phases and that are more robust and stable than using expression data alone. The accuracy of our algorithm was evaluated using cross-validation on the gene expression data. We then tested the hypothesis that gene sets associated with advanced phase CML would predict relapse after allogeneic transplantation in 176 independent CP CML cases. Our gene signatures of advanced phase CML are predictive of relapse even after adjustment for known risk factors associated with transplant outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22296787      PMCID: PMC3307121          DOI: 10.1093/bioinformatics/bts059

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  49 in total

1.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

Review 2.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting.

Authors:  Alain Dupuy; Richard M Simon
Journal:  J Natl Cancer Inst       Date:  2007-01-17       Impact factor: 13.506

3.  Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

Authors:  Agnes S M Yong; Richard M Szydlo; John M Goldman; Jane F Apperley; Junia V Melo
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

4.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

5.  Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.

Authors:  Mohamad Mohty; Richard M Szydlo; Agnes S M Yong; Jane F Apperley; John M Goldman; Junia V Melo
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

6.  Identification of genes with abnormal expression changes in acute myeloid leukemia.

Authors:  Derek L Stirewalt; Soheil Meshinchi; Kenneth J Kopecky; Wenhong Fan; Era L Pogosova-Agadjanyan; Julia H Engel; Michelle R Cronk; Kathleen Shannon Dorcy; Amy R McQuary; David Hockenbery; Brent Wood; Shelly Heimfeld; Jerald P Radich
Journal:  Genes Chromosomes Cancer       Date:  2008-01       Impact factor: 5.006

7.  The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

Authors:  Mohamad Mohty; Agnes S M Yong; Richard M Szydlo; Jane F Apperley; Junia V Melo
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

8.  Gene expression changes associated with progression and response in chronic myeloid leukemia.

Authors:  Jerald P Radich; Hongyue Dai; Mao Mao; Vivian Oehler; Jan Schelter; Brian Druker; Charles Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen Friend; Peter S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 9.  Advanced CML: therapeutic options for patients in accelerated and blast phases.

Authors:  Neil P Shah
Journal:  J Natl Compr Canc Netw       Date:  2008-03       Impact factor: 11.908

Review 10.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

View more
  6 in total

Review 1.  An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein.

Authors:  Martin F Orth; Alex Cazes; Elke Butt; Thomas G P Grunewald
Journal:  Oncotarget       Date:  2015-01-01

Review 2.  Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System.

Authors:  Haneen Banjar; David Adelson; Fred Brown; Naeem Chaudhri
Journal:  Biomed Res Int       Date:  2017-07-25       Impact factor: 3.411

3.  Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia.

Authors:  Elke Butt; Katrin Stempfle; Lorenz Lister; Felix Wolf; Marcella Kraft; Andreas B Herrmann; Cristina Perpina Viciano; Christian Weber; Andreas Hochhaus; Thomas Ernst; Carsten Hoffmann; Alma Zernecke; Jochen J Frietsch
Journal:  Cells       Date:  2020-02-14       Impact factor: 6.600

Review 4.  Biomarkers for determining the prognosis in chronic myelogenous leukemia.

Authors:  Kendra Sweet; Ling Zhang; Javier Pinilla-Ibarz
Journal:  J Hematol Oncol       Date:  2013-07-19       Impact factor: 17.388

5.  LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.

Authors:  Jochen J Frietsch; Carolin Kastner; Thomas G P Grunewald; Hardy Schweigel; Peter Nollau; Janine Ziermann; Joachim H Clement; Paul La Rosée; Andreas Hochhaus; Elke Butt
Journal:  Oncotarget       Date:  2014-07-30

6.  Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.

Authors:  Andreas B Herrmann; Martha-Lena Müller; Martin F Orth; Jörg P Müller; Alma Zernecke; Andreas Hochhaus; Thomas Ernst; Elke Butt; Jochen J Frietsch
Journal:  J Cell Mol Med       Date:  2020-01-19       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.